Program
sasanlimab
Also written as “PF-06801591” and “Sasanlimab”.
In Pfizer's pipeline, Anti-PD-1
. Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Non-Muscle Invasive Bladder Neoplasms · Melanoma, led by Pfizer.
Furthest: phase 3, since Nov 13, 20194 company-led studies, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 41 open or running | phase 3since Nov 13, 2019 | Oct 6, 2015 | none ahead |
- Named in Pfizer’s own pipeline as
sasanlimab PF-06801591
, phase 3, as of Nov 3, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 6, 2015First study: phase 1 study in MelanomaFirst studyNCT02573259 · 147 enrolled · United States, Bulgaria, Korea, Republic of and more
- Nov 13, 2019Phase 3 study in Non-Muscle Invasive Bladder NeoplasmsNCT04165317 · 1,068 enrolled · United States, Australia, Belgium and more
- Nov 14, 2019Phase 2 study in Carcinoma, Non-Small-Cell LungNCT04181788 · 155 enrolled · China, Japan, Russia and more
- Sep 30, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungNCT04585815 · 34 enrolled · United States, Australia, Belgium and more
TargetBeta
“Anti-PD-1”the company's pipeline, read by Claude · source
“An inhibitor of the human inhibitory receptor programmed cell death 1 (PD-1; PDCD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sasanlimab targets and binds to PD-1 and blocks the interaction between PD-1 and its ligands, PD-1 ligand 1 (PD-L1) …”NCIt, read by Claude
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04585815Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more | 2 | Terminated | May 17, 2023 | 34 |
| NCT04181788Carcinoma, Non-Small-Cell Lung · China, Japan, Russia and more | 2 | Completed | Mar 3, 2022 | 155 |
| NCT04165317Non-Muscle Invasive Bladder Neoplasms · United States, Australia, Belgium and more | 3 | Active, not recruiting | Dec 2, 2024 | 1,068 |
| NCT02573259Melanoma · United States, Bulgaria, Korea, Republic of and more | 1 | Completed | Nov 19, 2020 | 147 |
How it is read
Names in the registry
- “PF-06801591”, 4 entries
- “Sasanlimab”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Non-Muscle Invasive Bladder Neoplasms, 1 study
- Melanoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.